References
- Hannedouche T, Landais P, Goldfarb BEl, Esper N, Fournier A, Godin M, Durand D, Chenard J, Mignon F, Sue J-M, Grünfeld J-P. Randomised controlled trial of enalapril and P-blockers in non-diabetic chronic renal failure. Br Med J 1994; 309: 833–77
- Maschio G, Alberti D, Janin G, Locatelli F, Mann J, Motolese M, et al. Effect of the angi-otensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med 1996; 334: 939–45
- Brunner F P, Theil G, Hermle M, et al. Long-term enalapril and verapamil in rats with reduced renal mass. Kidney Int 1989; 36: 969–77
- Dworkin L D, Benstein J A, Parker M, et al. Calcium antagonists and converting enzyme inhibitors reduce renal injury by different mechanisms. Kidney Int 1993; 43: 808–14
- Tolins J P, Raij L. Comparison of converting enzyme inhibitor and calcium channel blocker in hypertensive glomerular injury. Hypertension 1990; 16: 452–61
- Zucchelli P, Zuccala A, Borghi M, Fusaroli M, Sasdelli M, Stallone C, et al. Long-term comparison between captopril and nifedipine in the progression of renal insufficiency. Kidney Int 1992; 42: 452–8
- Brøchner-Mortensen J, Rødbro P. Selection of routine method for determination of glomerular filtration rate in adult patients. Scand J Clin Lab Invest 1976; 36: 35–43
- Pedersen E B, Eiskjaer H, Madsen B, Danielsen H, Egeblad M, Nielsen CB. Effect of captopril on renal extraction of renin, angiotensin II, atrial natriuretic peptide and vasopressin, and renal vein renin ratio in patients with arterial hypertension and unilateral renal artery disease. Nephol Dial Transplant 1993; 8: 1064–70
- Jensen K T, Pedersen EB. A new radioimmunoassay for brain natriuretic peptide in plasma and reference values in different diseases. Scand J Clin Lab Invest 1997, In press
- Brenner BM. Nephron adaptation to renal injury or ablation. Am J Physiol 1985; 249: F324–F337
- Jackson B, Johnston CI. The contribution of systemic hypertension to progression of chronic renal failure in the rat remnant kidney: effect of treatment with an angiotensin converting enzyme inhibitor or a calcium inhibitor. J Hypertens 1988; 6: 495–501
- Anderson S, Rennke H G, Brenner BM. Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension. J Clin Invest 1986; 77: 1993–2000
- Loutzenhiser R D, Epstein M. Calcium antagonists and renal hemodynamics. Am J Physiol 1985; 249: F619–F629
- Romero C, Raij L, Granger J P, et al. Multiple effects of calcium entry blockers on renal function in hypertension. Hypertension 1987; 10: 140–51
- Bergström J, Alvestrand A, Bucht A, Gutierrez A. Progression of chronic renal failure in man is retarded with more frequent clinical follow-ups and better blood pressure control. Clin Nephrol 1986; 25: 1–6
- Brazy P C, Fitzwilliam JF. Progressive renal disease: role of race and antihypertensive medications. Kidney Int 1990; 37: 1113–9
- Mann J FE, Reisch C, Ritz E. Use of angiotensin converting enzyme inhibitors for preservation of kidney function. Nephron 1990; 55: 38–42, Suppl 1
- Rodicio J L, Alcazar J M, Ruilope JL. Influence of converting enzyme inhibition on glomerular filtration and proteinuria. Kidney Int 1990; 38: 590–4
- Rekola S, Bergstrand A, Bucht H. Deterioration rate in hypertensive IgA nephropathy: comparison of an converting enzyme inhibitor and beta-blocking agents. Nephron 1991; 59: 57–60
- Bianchi S, Bigazzi R, Baldari G, Campese VM. Long-term effects of enalapril and nicardipine on urinary albumin excretion in patients with chronic renal insufficiency: a 1-y follow-up. Am J Nephrol 1991; 11: 131–7
- Kampner A, Strangaard L, Leyssac SP. Effect of enalapril on the progression of chronic renal failure. Am J Hypertens 1992; 5: 423–30
- Weidmann P, Boehlen LM., de Courten M. Effects of different antihypertensive drugs on human diabetic proteinuria. Nephrol Dial Transplant 1993; 8: 582–4
- Brøckner-Mortensen J. Current status on assessment and measurement of glomerular filtration rate. Clin Physiol 1985; 5: 1–17